Sweet Heart – Contributions of Metabolism in the Development of Heart Failure in Diabetes Mellitus

Abstract

With the rapidly increasing prevalence of type 2 diabetes mellitus the risk for cardiovascular events is increasing. Almost 2 of 3 patients who present with symptomatic CHD have abnormal glucose homeostasis. Patients with diabetes mellitus and cardiovascular disease have an unfavourable prognosis. The most important result of diabetes metabolism is the switch from carbohydrates and fatty acids as a source of energy to an excessive use of fatty acids. The adverse influence of diabetes mellitus extends to all components of the cardiovascular system, including microvasculature, the epicardial coronary arteries, the large conduit arteries and the heart, as well as the kidneys. Focus of this review is the myocardial metabolism in heart failure and diabetes mellitus.

diabetic cardiomyopathy - lipotoxicity - cardiac metabolism

References

• 1 An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.  Am J Physiol Heart Circ Physiol. 2006;  291 H1489-H1506
• 2 Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis.  J Biol Chem. 2002;  277 29424-29430
• 3 Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes.  Diabetes Care. 2003;  26 2433-2441
• 4 Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.  Lancet. 2000;  355 773-778
• 5 Carroll R, Carley AN, Dyck JR, Severson DL. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts.  Am J Physiol Endocrinol Metab. 2005;  288 E900-E906
• 6 Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy.  Circ Res. 2005;  96 225-233
• 7 Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy.  J Clin Invest. 2001;  107 813-822
• 8 Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction.  Philos Trans R Soc Lond B Biol Sci. 1999;  354 485-495
• 9 Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy.  Lancet. 1991;  338 973-976
• 10 Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, Vusse GJ van der, Bonen A, Glatz JF, Luiken JJ. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats.  Diabetes. 2004;  53 1655-1663
• 11 Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.  Nature. 1995;  378 785-789
• 12 Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.  J Am Coll Cardiol. 2002;  40 271-277
• 13 Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.  Proc Natl Acad Sci USA. 2003;  100 1226-1231
• 14 Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.  J Clin Invest. 2002;  109 121-130
• 15 Fulton D, Gratton JP, MacCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.  Nature. 1999;  399 597-601
• 16 Giles TD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations.  Cardiol Clin. 2004;  22 553-568
• 17 Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Arsdall M Van, Adrogue JV, Brown KK, Taegtmeyer H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.  Am J Physiol Endocrinol Metab. 2005;  289 E328-E336
• 18 Guimbal C, Kilimann MW. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression.  J Biol Chem. 1993;  268 8418-8421
• 19 Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy.  Am Heart J. 1991;  122 795-801
• 20 Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.  Circulation. 2007;  115 1371-1375
• 21 Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.  Am J Hypertens. 2005;  18 949-957
• 22 Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance.  Nature. 2006;  440 944-948
• 23 How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice.  Diabetes. 2006;  55 466-473
• 24 Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload.  Am J Physiol Heart Circ Physiol. 2003;  285 H1261-H1269
• 25 Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin.  J Biol Chem. 1999;  274 26761-26766
• 26 Ingwall JS. Is creatine kinase a target for AMP-activated protein kinase in the heart?.  J Mol Cell Cardiol. 2002;  34 1111-1120
• 27 Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function.  Circ Res. 2004;  95 135-145
• 28 Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance.  Diabetes. 2002;  51 3020-3024
• 29 Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes.  Circulation. 2001;  103 2668-2673
• 30 Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus.  Physiol Res. 2002;  51 597-604
• 31 Kannel WB. Incidence and epidemiology of heart failure.  Heart Fail Rev. 2000;  5 167-173
• 32 Kannel WB, MacGee DL. Diabetes and cardiovascular disease. The Framingham study.  Jama. 1979;  241 2035-2038
• 33 King KL, Okere IC, Sharma N, Dyck JR, Reszko AE, MacElfresh TA, Kerner J, Chandler MP, Lopaschuk GD, Stanley WC. Regulation of cardiac malonyl-CoA content and fatty acid oxidation during increased cardiac power.  Am J Physiol Heart Circ Physiol. 2005;  289 H1033-H1037
• 34 Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle.  Biochim Biophys Acta. 2005;  1736 163-180
• 35 Lamb HJ, Beyerbacht HP, Laarse A van der, Stoel BC, Doornbos J, Wall EE van der, Roos A de. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism.  Circulation. 1999;  99 2261-2267
• 36 Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Harkonen R, Luotolahti M, Borra R, Sundell J, Knuuti J, Nuutila P. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease.  Diabetes. 2006;  55 511-516
• 37 Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders.  Proc Natl Acad Sci USA. 1999;  96 7473-7478
• 38 Luiken JJ, Coort SL, Koonen DP, Bonen A, Glatz JF. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes.  Proc Nutr Soc. 2004;  63 251-258
• 39 Luiken JJ, Coort SL, Koonen DP, Horst DJ van der, Bonen A, Zorzano A, Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters.  Pflugers Arch. 2004;  448 1-15
• 40 Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients.  Am J Physiol Heart Circ Physiol. 2004;  287 H1225-H1231
• 41 Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart.  Lancet. 2004;  364 1786-1788
• 42 Neubauer S. The failing heart – an engine out of fuel.  N Engl J Med. 2007;  356 1140-1151
• 43 Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.  Circulation. 1997;  96 2190-2196
• 44 Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease.  Eur Heart J. 1995;  16 ((Suppl O)) 115-118
• 45 Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K. et al . 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.  Circulation. 1992;  86 1810-1818
• 46 Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.  Circulation. 1996;  93 1905-1912
• 47 O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.  Am J Cardiol. 2007;  100 899-904
• 48 Opie LH. Effect of fatty acids on contractility and rhythm of the heart.  Nature. 1970;  227 1055-1056
• 49 Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure.  Circulation. 2002;  106 606-612
• 50 Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation.  J Biol Chem. 1997;  272 29911-29918
• 51 Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women.  Circulation. 2004;  109 2191-2196
• 52 Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart.  Circulation. 2001;  104 2923-2931
• 53 Rosen P, Du X, Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol?.  Mol Cell Biochem. 1998;  188 103-111
• 54 Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.  J Clin Invest. 2001;  107 181-189
• 55 Schupp M, Kintscher U, Fielitz J, Thomas J, Pregla R, Hetzer R, Unger T, Regitz-Zagrosek V. Cardiac PPARalpha expression in patients with dilated cardiomyopathy.  Eur J Heart Fail. 2006;  8 290-294
• 56 Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy.  Rev Cardiovasc Med. 2003;  4 ((Suppl 6)) S50-S57
• 57 Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.  Faseb J. 2004;  18 1692-1700
• 58 Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction.  Apoptosis. 2000;  5 415-418
• 59 Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa.  Circulation. 2005;  112 3577-3583
• 60 Stanley WC, Lopaschuk GD, MacCormack JG. Regulation of energy substrate metabolism in the diabetic heart.  Cardiovasc Res. 1997;  34 25-33
• 61 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  Bmj. 2000;  321 405-412
• 62 Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy.  Curr Opin Cardiol. 2004;  19 336-340
• 63 Taegtmeyer H. Switching metabolic genes to build a better heart.  Circulation. 2002;  106 2043-2045
• 64 Taegtmeyer H, MacNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.  Circulation. 2002;  105 1727-1733
• 65 Taegtmeyer H, Passmore JM. Defective energy metabolism of the heart in diabetes.  Lancet. 1985;  1 139-141
• 66 Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action.  Nat Rev Mol Cell Biol. 2006;  7 85-96
• 67 Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake.  Diabetes. 2003;  52 614-620
• 68 Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism. IV. Myocardial metabolism in diabetes.  Am J Med. 1955;  18 385-396
• 69 Heerebeek L van, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, Velden J van der, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.  Circulation. 2008;  117 43-51
• 70 Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium.  Curr Diab Rep. 2003;  3 279-288
• 71 Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle.  Mol Cell Biochem. 1994;  133–134 51-66
• 72 Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy.  J Clin Invest. 2003;  111 419-426
• 73 Young ME, MacNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms.  Circulation. 2002;  105 1861-1870
• 74 Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.  Science. 2001;  293 1673-1677
• 75 Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity.  Proc Natl Acad Sci USA. 2000;  97 1784-1789

Correspondence